Ask Warren

Tdspharm

464280 · KOSDAQ · ₩464280 · 티디에스팜

₩4,685▼ ₩85 (1.78%)End-of-day · Oct 27, 2026 · End-of-day prices.
Trade
Alert me
Price · 1Y −50.42%
Market cap
₩26B
Enterprise value
₩12B
P/E
5.9×
P/B
0.6×
Dividend yield
0.0%
ROE
9.7%
Net margin
13.3%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−56.6% from the high

₩4,240Today: ₩4,600 – ₩4,755₩10,800

Returns

  • 1W−8.3%
  • 1M−13.9%
  • 3M−6.3%
  • 6M−49.4%
  • YTD−52.4%
  • 1Y−50.4%
Volume today
7,164
0.9× the 20-day average
Traded today
₩34M
Listed shares
5,530,000
EPS (12 months)
₩791
Earnings yield 16.9%
SellBuy
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.

Upcoming dates

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

XfWATGr/in@

Signals

43Quiet
  • BuzzQuietBuzz 43 of 100 (50 is a normal day for this stock).
  • MomentumWeak-14.8% over the last month; the price is below its 20-day average.

Signals describe activity, not recommendations. Not financial advice.

Tdspharm stock overview

Tdspharm (티디에스팜, KRX: 464280) is listed on KOSDAQ, in the Biotech & Pharma sector. The company develops and manufactures transdermal drug delivery systems (TDDS), which are patch-type external medicines that deliver drugs through the skin. Its shares closed at ₩4,685 on Oct 27, 2026, down 1.78% on the day, giving it a market value of ₩26B.

Key facts

Market cap
₩26B
Sector
Biotech & Pharma
Latest price change
−1.78%
As of
Oct 27, 2026
Main business
The company develops and manufactures transdermal drug delivery systems (TDDS), which are patch-type external medicines that deliver drugs through the skin.

Quick answers about Tdspharm

What does Tdspharm do?
The company develops and manufactures transdermal drug delivery systems (TDDS), which are patch-type external medicines that deliver drugs through the skin. Its main products are cataplasma (poultice) and plaster patches for conditions such as muscle pain, neuralgia and arthritis, sold mainly to pharmaceutical companies and drug wholesalers in Korea, with a small share exported. The company follows an ODM model, developing products itself and having them manufactured by contract manufacturers.
What is the market cap of Tdspharm?
The market capitalisation of Tdspharm was ₩26B at the close on Oct 27, 2026.
Who are the largest shareholders of Tdspharm?
According to the latest official filings, the largest reported holders are Kim Chul-jun (45.97%, as of Jun 24, 2026); Korea Securities Finance (3.95%, as of Apr 9, 2025).
When is the next earnings report from Tdspharm?
Korean companies rarely announce results dates in advance. Based on when Tdspharm filed the same report in past years, its next 3q results is expected around Nov 14, 2026.

Company profile

The company develops and manufactures transdermal drug delivery systems (TDDS), which are patch-type external medicines that deliver drugs through the skin. Its main products are cataplasma (poultice) and plaster patches for conditions such as muscle pain, neuralgia and arthritis, sold mainly to pharmaceutical companies and drug wholesalers in Korea, with a small share exported. The company follows an ODM model, developing products itself and having them manufactured by contract manufacturers.

Written by AI from the company's latest annual report.

Korean name
티디에스팜
Sector
Biotech & Pharma
Themes
Pharmaceuticals
CEO
김철준
Founded
Nov 2002
Listed
Aug 2024
Listed shares
5,530,000
Fiscal year ends
Month 12
Website
www.tdspharm.com

Similar companies

Recent filings

See all

Titles in Korean until English translations are added.

Also known as: Tdspharm / 티디에스팜 / 464280 / KRX:464280

Source: KRX statistical information